Chemed Corp banner

Chemed Corp
NYSE:CHE

Watchlist Manager
Chemed Corp Logo
Chemed Corp
NYSE:CHE
Watchlist
Price: 492.65 USD 0.15% Market Closed
Market Cap: $6.5B

Wall St Price Targets

CHE Price Targets Summary
Chemed Corp

Wall Street analysts forecast CHE stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CHE is 455.43 USD with a low forecast of 404 USD and a high forecast of 525 USD.

Lowest Forecast
Price Target
404 USD
18% Downside
Average Forecast
Price Target
455.43 USD
8% Downside
Highest Forecast
Price Target
525 USD
7% Upside
Chemed Corp Competitors:
Price Targets
APO
Apollo Global Management Inc
25% Upside
BLFS
BioLife Solutions Inc
12% Upside
SRFM
Surf Air Mobility Inc
565% Upside
TNDM
Tandem Diabetes Care Inc
93% Upside
BMRN
Biomarin Pharmaceutical Inc
54% Upside

Revenue
Forecast

4% / Year
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
4% / Year
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 4%. The projected CAGR for the next 3 years is 6%.

Gross Profit
Forecast

6% / Year
Past Growth
7% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
6% / Year
Past Growth
7% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Gross Profit has been 6%. The projected CAGR for the next 2 years is 7%.

Operating Income
Forecast

6% / Year
Past Growth
13% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss
6% / Year
Past Growth
13% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss

Over the last 13 years, the compound annual growth rate for Operating Income has been 6%. The projected CAGR for the next 3 years is 13%.

Pre-Tax Income
Forecast

7% / Year
Past Growth
13% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss
7% / Year
Past Growth
13% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 7%. The projected CAGR for the next 3 years is 13%.

Net Income
Forecast

9% / Year
Past Growth
14% / Year
Estimated Growth
Estimates Accuracy
-12%
Average Miss
9% / Year
Past Growth
14% / Year
Estimated Growth
Estimates Accuracy
-12%
Average Miss

Over the last 13 years, the compound annual growth rate for Net Income has been 9%. The projected CAGR for the next 3 years is 14%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is CHE's stock price target?
Price Target
455.43 USD

According to Wall Street analysts, the average 1-year price target for CHE is 455.43 USD with a low forecast of 404 USD and a high forecast of 525 USD.

What is the Revenue forecast for Chemed Corp?
Projected CAGR
6%

Over the last 13 years, the compound annual growth rate for Revenue has been 4%. The projected CAGR for the next 3 years is 6%.

What is the Gross Profit forecast for Chemed Corp?
Projected CAGR
7%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 6%. The projected CAGR for the next 2 years is 7%.

What is the Operating Income forecast for Chemed Corp?
Projected CAGR
13%

Over the last 13 years, the compound annual growth rate for Operating Income has been 6%. The projected CAGR for the next 3 years is 13%.

What is the Pre-Tax Income forecast for Chemed Corp?
Projected CAGR
13%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 7%. The projected CAGR for the next 3 years is 13%.

What is the Net Income forecast for Chemed Corp?
Projected CAGR
14%

Over the last 13 years, the compound annual growth rate for Net Income has been 9%. The projected CAGR for the next 3 years is 14%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett